Strategic partnerships are an integral part of our corporate strategy. We seek partnerships that leverage Cardiome’s and its partner’s strengths and capabilities. Through our lead product, vernakalant, and other development programs, Cardiome has demonstrated that it has the knowledge and expertise to advance compounds from the bench through late stage clinical trials all the way to regulatory approvals.
We seek partnerships that will strengthen and complement our existing expertise and product pipeline. Cardiome has a long history with ion-channel drug discovery and development in cardiovascular disease, and is interested in leveraging this ion-channel expertise in other therapeutic areas such as:
Cardiome’s lead product candidate, vernakalant, is being developed globally in collaboration with Merck. Cardiome retains co-promotion rights for vernakalant oral in the U.S. market.
Vernakalant IV was approved in September 2010 and has been launched in the European Union and other countries under the trade name BRINAVESS™ by Merck.